ClinicalTrials.gg
Active, not recruitingNCT05763199Updated Mar 12, 2026

Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy

A Phase 2 interventional study of AHCC and Chemotherapy in Ovarian Epithelial Carcinoma, Fallopian Tube Carcinoma and Peritoneal Carcinoma, sponsored by University of California, Davis. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by University of California, Davis · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 500 studies in Carcinoma, Ovarian Epithelial with a site in United States — 28 open to participants now, 50 under way, 8 of them phase 3. Carcinoma, Ovarian Epithelial · United States.

Planned enrollment
272nd of 381
20 · median 35
Started
2023
with 8 others
Phase 2
177 of 500
4 open now
Primary completion
2026-12
later than 15 of 49 live
Registered
476th of 500
by date

Among the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, this one is the 272nd largest by planned enrollment of the 381 interventional ones that give a count, is one of 9 that started in 2023, is one of 177 in phase 2, reaches primary completion later than 15 of the 49 other live ones, and was the 476th registered.

Carcinoma, Ovarian Epithelial

798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 101 are open to participants now.

Browse Carcinoma, Ovarian Epithelial studies →

Open to participants now

28 of the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 49 (65%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, or all of them as a file.
02

Study summary

This is a pilot phase, randomized, double-blinded feasibility pilot study of AHCC in participants with ovarian cancer.

Read the detailed description

This is a pilot phase, randomized, double-blinded feasibility pilot study of AHCC in participants with ovarian cancer. 20 women who plan to undergo adjuvant chemotherapy for ovarian cancer at the University of California (UC) Davis Health Comprehensive Cancer Center will be enrolled and randomized 1:1 to receive AHCC (3 grams by mouth daily) or placebo during standard of care chemotherapy. HRQOL and adverse events will be assessed at baseline and during chemotherapy. The hypothesis is that a randomized controlled trial of AHCC supplementation for ovarian cancer patients on adjuvant chemotherapy is feasible.

03

Conditions studied

  • Ovarian Epithelial Carcinoma
  • Fallopian Tube Carcinoma
  • Peritoneal Carcinoma

Keywords

  • AHCC
  • Standardized extract of cultured Lentinula edodes mycelia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed epithelial ovarian, fallopian tube or peritoneal carcinoma

    • High-grade or low-grade serous, mucinous, endometrioid, clear cell, mixed or other histologies allowed
  2. Clinical stage I-IV at diagnosis
  3. Treatment decision to include standard-of-care chemotherapy after primary or interval debulking surgery, or initial staging surgery. Chemotherapy should include a platinum and a taxane doublet.

    • Neoadjuvant chemotherapy is allowed (no will be required)
    • Any combination of platinum and taxane doublet is allowed (i.e., carboplatin, cisplatin, paclitaxel, or docetaxel)
    • Different schedules of platinum and taxane doublet are allowed (i.e., every 21 days, dose-dense or weekly)
    • Bevacizumab is allowed
  4. Age greater than or equal to 18 years of age
  5. English or Spanish-speaking individuals
  6. (ECOG) performance status less than or equal to 2 ( greater than or equal to 60%)
  7. Organ and bone marrow function defined by:

    • Leukocytes greater than or equal to 2,500/µL
    • greater than or equal to 1,000/µL
    • greater than or equal to 75,000/µL
    • greater than or equal to 8 g/dL
    • Total less than or equal to 1.5 × institutional (ULN) (however, patients with known Gilbert disease who have serum bilirubin level less than or equal to 3 x ULN may be enrolled)
    • (AST)/ alanine transaminase (ALT) less than or equal to 3 × ULN (AST and/or ALT less than or equal to 5 x ULN for patients with liver involvement)
    • Alkaline phosphatase less than or equal to 2.5 × ULN (less than or equal to 5 x ULN for patients with documented liver involvement or bone )
    • or (GFR) greater than or equal to 30 mL/min by Cockcroft-Gault or 30 mL/min/1.73m2
  8. Individuals of must agree to use adequate (hormonal or barrier method of birth control; abstinence) for the duration of study participation (including dosing interruptions) and for at least 5 months (150 days) after the last dose of study agent or the duration specified in the United Surgical Partners International (USPI) for any of the agents used in the adjuvant standard-of-care regimen, whichever is longest. Patients must agree to refrain from egg donation during this timeframe.
  9. Ability to understand and the willingness to sign a written document
  10. Patients with known (HIV) are allowed in the study, but HIV-positive patients must have:

    • A stable regimen of highly active anti-retroviral therapy (HAART)
    • No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections
    • A cluster of differentiation 4 (CD4) count above 250 cells/µL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests within the last year.

Exclusion criteria

Exclusion Criteria:

  1. History of allergic reactions to mushrooms
  2. History of allergic reaction to dextrin
  3. History of allergic reaction to rapeseed oil
  4. History of allergic reaction to corn
  5. Consumption of other supplements derived from mushrooms or basidiomycetes

    • Consumption of whole mushrooms through diet is acceptable
    • Consumption of a blend with unknown/ unclear mushrooms or basidiomycetes contents, then it is ok to include participant
  6. Current or prior (within 3 months of enrollment) use of medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (anti-TNF) agents). The following are exceptions to this criterion:

    • Intranasal, inhaled, topical or local injections (e.g., intra-articular injection); steroids as premedication for reactions; systemic corticosteroid at physiologic doses not to exceed 10 mg/day of prednisone or equivalent may be enrolled.
    • Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled.
    • The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.
  7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would interfere with patient safety or limit compliance with study requirements.
  8. Inability to swallow experimental agent or placebo
  9. History of gastrectomy or other malabsorption syndromes
  10. Subjects who are pregnant or breast-feeding
  11. Any condition that would prohibit the understanding or rendering of
  12. Any medical condition that in the opinion of the investigator would interfere with the patient's safety or compliance while on trial.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®)

    AHCC 3g PO Daily

    Dietary Supplement: AHCC · Drug: Chemotherapy

  • Placebo comparator
    Placebo

    Placebo PO Daily

    Drug: Chemotherapy · Other: Placebo

Interventions

  • Dietary supplementActive Hexose Correlated CompoundStudies of Active Hexose Correlated CompoundActive Hexose Correlated Compound pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    AHCC is the cultured mycelia of Lentinula edodes mushrooms from the Basidiomycetes family.

    Also known as: A standardized extract of cultured Lentinula edodes mycelia

  • DrugChemotherapy

    Chemotherapy will be administered per standard of care.

    Also known as: Platinum and taxane chemotherapy

  • OtherPlacebo

    Dextrin

06

What researchers measure

Primary outcomes

  1. Proportion of participants consent and randomized to taking AHCC or placebo during adjuvant chemotherapy compared to to total number of ovarian cancer patients eligible for the trial following prescreening and participation invitation.

    Time frame: Study activation to randomization of 20th participant

  2. Time required to randomize 20 participants

    Time frame: Study activation to randomization of 20th participant.

  3. Proportion of participants that complete study treatment

    Time frame: First dose through Cycle 3-6 post adjuvant chemotherapy; each cycle is 3 weeks

Secondary outcomes

  1. Proportion of participants that adhere to taking study treatment

    Time frame: First dose through Cycle 3-6 post adjuvant chemotherapy; each cycle is 3 weeks

  2. Adherence to taking study treatment for each participant

    Time frame: First dose through Cycle 3-6 post adjuvant chemotherapy; each cycle is 3 weeks

  3. Proportion of participants that adhere to completing the Functional Assessment of Cancer Therapy - Ovarian (FACT-O)

    All health-related quality of life assessments use a 5 point Likert-type scale and is scored based on a manual scoring template, some items are reverse scored; the higher the score, the better the quality of life.

    Time frame: Baseline through 30d post last dose

  4. Proportion of participants that adhere to completing the Functional Assessment of Cancer Therapy/ Gynecologic Oncology Group - Neurotoxicity (FACT/ GOG-NTX)

    All health-related quality of life assessments use a 5 point Likert-type scale and is scored based on a manual scoring template, some items are reverse scored; the higher the score, the better the quality of life.

    Time frame: Baseline through 30d post last dose

  5. Proportion of participants that adhere to completing the Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES)

    All health-related quality of life assessments use a 5 point Likert-type scale and is scored based on a manual scoring template, some items are reverse scored; the higher the score, the better the quality of life.

    Time frame: Baseline through 30d post last dose

  6. Participant experience self-reported in the acceptability questionnaire compared to self-reported anticipated acceptability

    The acceptability questionnaire measures the following ordinal data listed in order of most acceptable to least acceptable: strongly agree, agree, neutral, disagree, and strongly disagree.

    Time frame: Baseline and at end of treatment (about 9-18 weeks post adjuvant chemotherapy)

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Dec 2026, 40 months after the start.

Of 51 phase 2 interventional studies under Carcinoma, Ovarian Epithelial, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 92. This study's planned 40 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2023
First posted
Mar 10, 2023
StartActual
Aug 1, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 1, 2027
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05763199
Collaborators
Amino Up Chemicals Co., Ltd.
Responsible party
Hui Amy Chen (Assistant Professor, University of California, Davis) — Principal investigator
First posted
Mar 10, 2023
Start date
Aug 1, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Mar 12, 2026

Study contacts

Hui Chen, MD
principal investigator · University of California, Davis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Active Hexose Correlated Compound

Start the discussion